FGF19 and hepatocellular carcinoma: Receptor tyrosine kinase (RAS-RAF-MAPK) and phosphatidylinositol-3-kinase, Protein kinase B and mammalian target of rapamycin (PI3K-AKT-mTOR) pathways are usually activated in HCC, owing to the amplification of regions that includes FGF19 (5% tumors) and mutations in RPS6KA3 and RSK2 (5–9% cases) [16,20].